Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06237257

A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer

Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd

Conditions Locally Advanced Cervical Cancer

Interventions Cisplatin Injection/Carboplatin Injection External Beam Radiotherapy (EBRT)/Brachytherapy Paclitaxel Injection SHR-1316

Updated 5 times since 2024 Last updated: Dec 19, 2024 Started: Mar 20, 2024 Primary completion: Dec 31, 2024 Completion: Jan 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06237257, this PHASE2 trial focuses on Locally Advanced Cervical Cancer and remains ongoing. Sponsored by Shanghai Shengdi Pharmaceutical Co., Ltd, it has been updated 5 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Jan 2025 — Present [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Sep 2024 — Jan 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
May 2024 — Jul 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Mar 2024 — May 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Shengdi Pharmaceutical Co., Ltd

Data source: Shanghai Shengdi Pharmaceutical Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China